[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Item 1 of about 1
1. Gutermuth J, Audring H, Voit C, Trefzer U, Haas N: Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Venereol; 2004 Jul;18(4):477-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma.
  • BACKGROUND: Eccrine porocarcinoma (EP) is a rare malignant tumour arising in the acrosyringium, with about 50% of the cases developing local recurrence or metastatic disease.
  • No standard therapy protocols for metastatic disease exist.
  • In the past, only short remissions were achieved by applying combinations of cytotoxic agents, which were associated with severe side-effects.
  • AIM OF THE STUDY: In the case reported here, the aim was to find a protocol with fewer side-effects for a patient who was not willing to undergo extensive polychemotherapy.
  • SUBJECT: A 67-year-old male patient with local recurrence and regional lymph node metastases after resection of EP was treated with a combination of interferon-alpha (IFN-alpha) 9 million units s.c. three times per week and paclitaxel 100 mg/m(2) weekly i.v., which shows a side-effect profile similar to taxotere and is used in the treatment of a variety of neoplasms such as advanced squamous cell carcinoma.
  • MAIN OUTCOME: This less aggressive treatment was tolerated well and the patient responded with minor remission and long-term stable disease.
  • [MeSH-major] Acrospiroma / drug therapy. Acrospiroma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Interferon-alpha / administration & dosage. Lymphatic Metastasis. Male. Paclitaxel / administration & dosage. Recombinant Proteins

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196167.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement





Advertisement